HUP0100432A2 - Vírusellenes hatású piridinszármazékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására - Google Patents

Vírusellenes hatású piridinszármazékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására

Info

Publication number
HUP0100432A2
HUP0100432A2 HU0100432A HUP0100432A HUP0100432A2 HU P0100432 A2 HUP0100432 A2 HU P0100432A2 HU 0100432 A HU0100432 A HU 0100432A HU P0100432 A HUP0100432 A HU P0100432A HU P0100432 A2 HUP0100432 A2 HU P0100432A2
Authority
HU
Hungary
Prior art keywords
chm
alkyl
unsaturated bonds
nnr5r6
substituents
Prior art date
Application number
HU0100432A
Other languages
English (en)
Inventor
Per Engelhardt
Marita Högberg
Rolf Noréen
Christer Sahlberg
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9800113A external-priority patent/SE9800113D0/xx
Priority claimed from SE9800116A external-priority patent/SE9800116D0/xx
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of HUP0100432A2 publication Critical patent/HUP0100432A2/hu
Publication of HUP0100432A3 publication Critical patent/HUP0100432A3/hu
Publication of HU228886B1 publication Critical patent/HU228886B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát az (I) és (II) általános képletű vegyületek,valamint ezeket tartalmazó gyógyászati készítmények képezik. Az (I)általános képletben Rx jelentése cianocsoport vagy brómatom; R1jelentése halogénatom; és R2 jelentése 1-3 szénatomos alkilcsoport. Az(II) általános képletben Rx R1és R2 jelentése a fentiekben megadottalazonos, R3 jelentése H, (CHm)nR5R6; R4 jelentése H, 1-3 szénatomosalkilcsoport, (CHm)nNR5R6, (CHm)nC(=O)R5, (CHm)nOH, OR7, halogénatom,CF3 vagy CN csoport; vagy R3 és R4 együttes jelentése 5- vagy 6-tagúkondenzált gyűrű, amelyben 0-2 heteroatom és/vagy 0-2 telítetlen kötésés/vagy 0-2 szubsztituens van jelen; R5 jelentése H, 1-3 szénatomosalkilcsoport, C(=O)R7 vagy 1-4 aminosavból álló peptid; R6 jelentéseH, 1-3 szénatomos alkilcsoport; vagy R5 és R6 együttes jelentése 5-vagy 6-tagú gyűrű, amelyben 0 vagy 1 további heteroatom és/vagy 0-2telítetlen kötés és/vagy 0-2 szubsztituens van jelen; R7 jelentése H,1-12 szénatomos alkilcsoport, (CHm)nNR5R6; X és az ezt körülvevő gyűrűjelentése 5- vagy 6-tagú gyűrű, amelyben 0-3 telítetlen kötés és/vagy0-3 heteroatom van jelen kénatom, oxigénatom és nitrogénatom közülválasztva; m értéke egymástól függetlenül 1 vagy 2; n értéke egymástólfüggetlenül 0, 1 vagy 2; p értéke 0 vagy 1. A találmány szerintivegyületek vírusellenes szerként alkalmazhatók különösen HIV reverztranszkriptáz gátlására. Ó
HU0100432A 1998-01-16 1999-01-15 Antiviral compounds, process for producing them and pharmaceutical compositions containing them HU228886B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9800113A SE9800113D0 (sv) 1998-01-16 1998-01-16 Antivirals II
SE9800116A SE9800116D0 (sv) 1998-01-16 1998-01-16 Antivirals I
PCT/SE1999/000053 WO1999036406A1 (en) 1998-01-16 1999-01-15 Antivirals

Publications (3)

Publication Number Publication Date
HUP0100432A2 true HUP0100432A2 (hu) 2001-07-30
HUP0100432A3 HUP0100432A3 (en) 2002-12-28
HU228886B1 HU228886B1 (en) 2013-06-28

Family

ID=26663191

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100432A HU228886B1 (en) 1998-01-16 1999-01-15 Antiviral compounds, process for producing them and pharmaceutical compositions containing them

Country Status (26)

Country Link
US (2) US6486183B1 (hu)
EP (1) EP1054867B1 (hu)
JP (1) JP4488621B2 (hu)
KR (1) KR100566445B1 (hu)
CN (2) CN1522698A (hu)
AR (1) AR016169A1 (hu)
AT (1) ATE264305T1 (hu)
AU (1) AU739766B2 (hu)
BR (1) BR9906933A (hu)
CA (1) CA2318694C (hu)
CZ (1) CZ299387B6 (hu)
DE (1) DE69916425T2 (hu)
DK (1) DK1054867T3 (hu)
EA (1) EA003327B1 (hu)
ES (1) ES2220039T3 (hu)
HK (1) HK1036280A1 (hu)
HU (1) HU228886B1 (hu)
IL (1) IL137196A0 (hu)
MY (1) MY129292A (hu)
NZ (1) NZ505543A (hu)
PL (1) PL191832B1 (hu)
PT (1) PT1054867E (hu)
SK (1) SK285779B6 (hu)
TR (1) TR200002058T2 (hu)
TW (1) TW470645B (hu)
WO (1) WO1999036406A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100566445B1 (ko) * 1998-01-16 2006-03-31 메디비르 아베 항바이러스제
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
SE0100733D0 (sv) * 2001-03-05 2001-03-05 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
SE0102867D0 (sv) 2001-08-28 2001-08-28 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
US7915295B2 (en) * 2004-01-08 2011-03-29 Medivir Ab Non-nucleotide reverse transcriptase inhibitors
WO2007026156A1 (en) * 2005-08-31 2007-03-08 Cipla Limited Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
US7302330B1 (en) * 2006-09-01 2007-11-27 Gm Global Technology Operations, Inc. Torque converter clutch dynamic control
GB0623258D0 (en) 2006-11-22 2007-01-03 Remynd Nv Thiadiazole derivatives for the treatment of neuro-degenerative diseases
EP2598482B1 (en) * 2010-07-29 2018-04-04 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
AU2013229274A1 (en) 2012-03-05 2014-09-04 Cipla Limited Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0706514T3 (da) * 1993-08-24 1999-08-02 Medivir Ab Forbindelser og fremgangsmåder til inhibering af HIV og relaterede vira
US5849769A (en) * 1994-08-24 1998-12-15 Medivir Ab N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
KR100566445B1 (ko) * 1998-01-16 2006-03-31 메디비르 아베 항바이러스제

Also Published As

Publication number Publication date
TW470645B (en) 2002-01-01
AR016169A1 (es) 2001-06-20
PT1054867E (pt) 2004-09-30
HK1036280A1 (en) 2001-12-28
DE69916425T2 (de) 2005-05-19
CN1158261C (zh) 2004-07-21
JP2002509137A (ja) 2002-03-26
JP4488621B2 (ja) 2010-06-23
CN1522698A (zh) 2004-08-25
PL341819A1 (en) 2001-05-07
HUP0100432A3 (en) 2002-12-28
US6486183B1 (en) 2002-11-26
ATE264305T1 (de) 2004-04-15
MY129292A (en) 2007-03-30
HU228886B1 (en) 2013-06-28
AU739766B2 (en) 2001-10-18
CA2318694A1 (en) 1999-07-22
EP1054867B1 (en) 2004-04-14
EA200000770A1 (ru) 2000-12-25
CA2318694C (en) 2009-10-27
AU2445099A (en) 1999-08-02
WO1999036406A1 (en) 1999-07-22
DK1054867T3 (da) 2004-08-09
NZ505543A (en) 2002-09-27
EP1054867A1 (en) 2000-11-29
CN1292781A (zh) 2001-04-25
KR20010034194A (ko) 2001-04-25
CZ299387B6 (cs) 2008-07-09
TR200002058T2 (tr) 2001-05-21
US20030119881A1 (en) 2003-06-26
PL191832B1 (pl) 2006-07-31
CZ20002604A3 (en) 2001-05-16
US7148243B2 (en) 2006-12-12
IL137196A0 (en) 2001-07-24
BR9906933A (pt) 2001-11-27
KR100566445B1 (ko) 2006-03-31
ES2220039T3 (es) 2004-12-01
DE69916425D1 (de) 2004-05-19
EA003327B1 (ru) 2003-04-24
SK285779B6 (sk) 2007-08-02
SK10332000A3 (sk) 2002-04-04

Similar Documents

Publication Publication Date Title
HUP0100432A2 (hu) Vírusellenes hatású piridinszármazékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
HUP0401083A2 (hu) 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
FI112485B (fi) Uusia 1,4-dihydro-4-okso-1,8-naftyridiinijohdannaisia, menetelmä niiden valmistamiseksi ja kasvaintenvastaisia aineita
HUP0204410A2 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP9904703A2 (hu) Aminotiofén-karbonsav-amidok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP0302480A2 (hu) Piridinonszármazékok ateroszklerózis kezelésére, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0004082A2 (hu) Adenozinszármazékok, eljárás előállításukra azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint ilyen hatóanyagok alkalmazása gyógyszerkészítmények előállítására
HUP0001498A2 (hu) Farnezil-transzferáz-gátló 1,8-anellált imidazolil-kinolinon-származékok, intermedierjeik, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HK1063781A1 (en) Pyrazole derivatives for treating hiv
HUP0004106A2 (hu) Új adenozinszármazékok, eljárás előállításukra, azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint ilyen hatóanyagok alkalmazása gyógyszerkészítmények előállítására
HUP0301099A2 (hu) Helyettesített ftalocianinok és prekurzoraik
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
HUP0001294A2 (hu) Proteáz inhibitor hatású (heterociklil-karbonil)-hidrazid-származékok, eljárás előállításukra és alkalmazásuk
HUT70194A (en) Quinoline- or quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
SE8600260D0 (sv) Substituerade indolokinoxaliner
HUP9904682A2 (hu) Fenil-oxazol- és -tiazol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DE3889057D1 (de) Verbindungen für die Induktion der in vitro- und in vivo-Erzeugung von Cytokinen.
HUP0401762A2 (hu) Szubsztituált benzo [b] azepin-2-on-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0101230A2 (hu) Eljárás 2-[(2-piridil)-metilszulfinil]-1H-benzimidazol-származékok előállítására
HUP0401831A2 (hu) Szubsztituált 1H-kinolin-2-on-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0303716A2 (hu) Piridin-2-il-amino-alkil-karbonil-glicil-béta-alanin és származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69320367D1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
HUP0300265A2 (hu) Aril- és heteroaril-szulfonátok, eljárás előállításukra és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP9802645A2 (hu) Új metalloproteináz inhibitorok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
HUP0001180A2 (hu) Új eritromicinszármazékok, eljárás előállításukra és gyógyszerként történő alkalmazásuk

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees